circRHOBTB3 Suppresses Prostate Cancer Proliferation and Metastasis via NONO Cytoplasmic Retention

Study Background and Research Question

Prostate cancer (PCa) remains the most commonly diagnosed malignancy among men, with metastatic forms posing significant therapeutic challenges and contributing to high mortality rates. The molecular drivers of metastatic progression are incompletely understood, particularly regarding the roles of noncoding RNAs such as circular RNAs (circRNAs). CircRNAs, once considered transcriptional byproducts, have recently emerged as important regulators in cancer biology, with potential as both biomarkers and therapeutic targets. However, the specific functions and mechanisms of circRNAs in prostate cancer remain underexplored. This study (Song et al., 2025) aimed to identify circRNAs involved in PCa metastasis and delineate their mechanistic roles in disease progression.

Key Innovation from the Reference Study

The central innovation of this research is the identification and functional characterization of circRHOBTB3 (hsa_circ_0007444), a circRNA derived from exons 6–7 of the RHOBTB3 gene, as a suppressor of prostate cancer proliferation and metastasis. Notably, the study demonstrates that circRHOBTB3 exerts its tumor-suppressive effect by binding to the non-POU domain-containing octamer-binding protein (NONO), a transcriptional regulator of monoamine oxidase A (MAOA). By promoting cytoplasmic retention of NONO, circRHOBTB3 prevents NONO from activating MAOA transcription, resulting in reduced MAOA expression and, consequently, diminished PCa cell proliferation and metastatic potential. This represents a novel RNA-mediated mechanism for the suppression of metastatic prostate cancer.

Methods and Experimental Design Insights

The investigators used a combination of high-throughput sequencing, in vitro and in vivo functional assays, and molecular interaction studies to elucidate the role of circRHOBTB3 in prostate cancer. Key methodological elements include:

• Development of a highly metastatic PCa cell model to compensate for the scarcity of metastatic tissue samples.
• Cross-analysis of sequencing data from both PCa tissues and the metastatic cell model to identify differentially expressed circRNAs.
• Characterization of circRHOBTB3 expression patterns across clinical PCa samples and correlation with pathological stage and grade.
• Functional assays (proliferation, migration, invasion) in cell lines with manipulated circRHOBTB3 levels to assess its effects on tumorigenic properties.
• RNA pulldown and immunoprecipitation to confirm circRHOBTB3–NONO interaction and subcellular localization studies (e.g., FISH, immunofluorescence) to track NONO distribution.
• In vivo xenograft models to validate the impact of circRHOBTB3 expression on tumor growth and metastatic spread.
• Investigation of the regulation of circRHOBTB3 biogenesis, specifically the role of serine/arginine-rich splicing factor 9 (SRSF9) in interacting with Alu elements in flanking introns.

Core Findings and Why They Matter

The study provides several key findings:

• CircRHOBTB3 is downregulated in PCa: Lower levels of circRHOBTB3 are significantly associated with advanced pathological T stage, higher clinical M stage, and elevated D’Amico grade, indicating a link to aggressive disease (Song et al., 2025).
• Tumor-suppressive function: Functional experiments show that overexpression of circRHOBTB3 inhibits PCa cell proliferation, migration, and invasion both in vitro and in mouse xenograft models.
• Molecular mechanism: circRHOBTB3 binds NONO in the cytoplasm, preventing its nuclear translocation. This disrupts NONO-mediated MAOA transcriptional activation, reducing MAOA levels, which in turn suppresses PCa cell growth and metastasis.
• Regulation of circRHOBTB3 formation: The splicing factor SRSF9 interacts with AluSx and AluJb elements, negatively regulating circRHOBTB3 biogenesis, highlighting another layer of circRNA regulation in cancer.

These findings are significant because they reveal a previously unappreciated layer of post-transcriptional regulation in metastatic prostate cancer. The circRHOBTB3–NONO–MAOA axis provides a clear molecular pathway through which circRNAs can modulate tumor behavior. Given the tissue-specific and stable nature of circRNAs, circRHOBTB3 could serve as both a biomarker for aggressive disease and a potential therapeutic target.

Comparison with Existing Internal Articles

Several internal resources discuss the targeting of focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2) in cancer research, particularly with the use of the FAK/Pyk2 inhibitor PF-562271 HCl. For instance, the article "PF-562271 HCl: Reliable FAK/Pyk2 Inhibition for Cancer Research" emphasizes the importance of robust, reproducible inhibition of FAK/Pyk2 signaling in cell proliferation and migration assays. Similarly, "PF-562271 HCl and the Future of FAK/Pyk2 Inhibition" integrates new circRNA-driven paradigms, highlighting the intersection of kinase signaling and noncoding RNA regulation in tumor progression. While the reference study primarily focuses on a circRNA-NONO-MAOA axis rather than kinase inhibition, there is conceptual overlap in targeting post-transcriptional and signaling pathways that govern metastatic behavior. Both approaches underscore the value of dissecting molecular networks—be they RNA-protein interactions or kinase cascades—in advancing cancer therapeutics. Researchers leveraging FAK/Pyk2 inhibitors may find additional benefit in considering the interplay between kinase signaling and circRNA-mediated regulation, as suggested by recent integrative reviews.

Limitations and Transferability

The study presents a robust mechanistic framework; however, certain limitations are evident:

• Model system constraints: The reliance on cell lines and xenograft models may not fully capture the complexity of human metastatic prostate cancer, including tumor microenvironmental influences.
• Clinical translation: While low circRHOBTB3 expression correlates with advanced disease, prospective studies are needed to validate its utility as a clinical biomarker or therapeutic target.
• Specificity of RNA interactions: The possibility of additional, yet unidentified, circRHOBTB3 binding partners or downstream targets remains, warranting further investigation.

Despite these limitations, the mechanistic insights gained are likely transferable to other malignancies where circRNAs and RNA-binding proteins orchestrate gene regulatory networks.

Protocol Parameters

• circRHOBTB3 overexpression: Achieved via lentiviral transduction in PCa cell lines; functional readouts assessed after 48–72 hours.
• NONO subcellular localization: Tracked using immunofluorescence and FISH, typically after 24–48 hours of circRHOBTB3 modulation.
• Tumor growth and metastasis assays: In vivo xenograft studies conducted with weekly monitoring of tumor volume and metastatic spread post-cell injection.
• MAOA transcriptional analysis: Quantified by qPCR and western blot following circRHOBTB3 or NONO manipulation, using standard protocols for RNA and protein isolation.
• Regulation of circRHOBTB3 biogenesis: SRSF9 knockdown or overexpression performed in vitro with assessment of circRNA levels after 48 hours.

Research Support Resources

For researchers aiming to investigate kinase signaling alongside circRNA-driven pathways in cancer models, validated FAK/Pyk2 inhibitors such as PF-562271 HCl (SKU A8345) from APExBIO offer a reliable option for modulating focal adhesion kinase signaling. PF-562271 HCl demonstrates high selectivity and potency in FAK phosphorylation inhibition, supporting studies of tumor growth inhibition and microenvironment modulation. Integrating such tools into experimental workflows can facilitate a more comprehensive understanding of metastatic mechanisms and therapeutic vulnerabilities.